12:00 AM
 | 
May 03, 1999
 |  BC Week In Review  |  Clinical News  |  Regulatory

North American Vaccine regulatory update

Austria granted marketing approval for NVX's DTaP, a combined diphtheria, tetanus and acellular pertussis...

Read the full 48 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >